Summary Seeking a summer intern with strong interest in computer-aided drug design and chemoinformatics. Job Category Interns & Co-ops Requisition Number 33899BR Job Description This is a full-time summer internship from June-August 2018 located in Cambridge, MA. Seeking a summer intern with strong interest in computer-aided drug design and chemoinformatics. Key Responsibilities: \u2022 Build and implement new protocols on a cloud computing platform for performing data analysis (machine learning), library design and\/or molecular dynamics simulations. Qualifications \u2022 Programming experience with Python is required. Working knowledge of the structure-based design and cheminformatics methods as well as a sound background in chemistry, biology, statistics, mathematics are desirable. \u2022 Excellent communication, reporting and team working skills. To participate in the Biogen Intern Program, students must meet the following eligibility criteria: \u2022 Legal authorization to work in the U.S. \u2022 Enrollment in a full-time undergraduate or graduate program, returning to the academic program following Biogen intern assignment \u2022 Minimum grade point average of 3.2 (preferred) \u2022 At least 18 years of age prior to the scheduled start date \u2022 Completed at least one year of undergraduate studies Education \u2022 Must be pursuing B.S. or higher degree in Computational Chemistry or related areas. Employment Category Full-Time Regular Experience Level Internship or Co-op
Website : https://www.biogen.com
We measure success by our impact on the patients we serveBiogen, Inc. (previously known as Biogen Idec) is an American global biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.iogen was founded in 1978 in Geneva by several prominent biologists, including Kenneth Murray of the University of Edinburgh, Phillip Allen Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase), Heinz Schaller, University of Heidelberg and Charles Weissmann, University of Zurich (who contributed the first product interferon alpha). Gilbert and Sharp were subsequently honored with Nobel Prizes: Gilbert was recognized in 1980 with the Nobel Prize in Chemistry for his work in understanding DNA sequencing, while Sharp received the Nobel Prize in Physiology or Medicine in 1993 for his discovery of split genes.